News

The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan and erlotinib. The trial is expected to enroll up

Pending the receipt of all necessary regulatory approvals, Angiotech anticipates launching the commercial 5-fluorouracil-coated (5-FU) central venous catheter (CVC) product line in 2008. William Hunter, president and CEO

The existing principal shareholders, Rolf and William Schmidt, also converted existing loans totaling approximately $16 million into convertible preferred stock. The financing will be used to fund a

Ambrx said that the collaboration will apply its protein optimization technology, ReCODE, with Lilly’s expertise in biologics discovery, development and commercialization to pursue first-in-class or best-in-class drug candidates,

The transaction is expected to be completed by the end of January 2008, subject to customary regulatory approvals, at which time Bristol-Myers Squibb Medical Imaging (BMS MI) will

A complete response letter is issued by FDA’s Center for Biologics Evaluation and Research when the review of a file is completed and questions remain to be answered

According to the results, asenapine 5mg twice daily and 10mg twice daily were both significantly more effective than placebo at improving patient positive and negative syndrome scale (PANSS)

Accordingly, Lilly and BioMS Medical will collaborate on the development of MBP8298 and will also share in certain development costs with Lilly being responsible for future R&D, manufacturing

On issuance, the patent will expire in 2022. The company said that the subsequently filed patent applications which broaden its patent position could extend the patent life for